Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy 3-month old infants (85-119 days, inclusive) at time of Visit 1 whose parents/legal guardians have given written informed consent after the nature of the study has been explained.~2. Available for all the visits scheduled in the study.~3. In good health as determined by medical history, physical examination and clinical judgment of the investigator.~Exclusion Criteria:~1. History of any previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s) at the time of enrollment.~2. Previous known or suspected disease caused by N. meningitidis.~3. Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection or colonization.~4. History of severe allergic reaction after previous vaccinations, or hypersensitivity to any component of the vaccine.~5. Known or suspected autoimmune disease or impairment/alteration of the immune system resulting from, for ex-ample:~   * Chronic administration of immunosuppressants or other immune-modifying drugs since birth (3 months prior). (For corticosteroids, this means prednisone, or equivalent, ≥ 0.5 mg/kg/day or ≥ 10 mcg/day for children below 2 years. Inhaled and topical steroids are allowed),~  * Immune deficiency disorder, or known HIV infection.~6. Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation since birth.~7. History of any progressive or severe neurologic disorder, or seizure disorder or Guillan Barré syndrome (exception: one self-limited febrile seizure is acceptable).~8. History of any bleeding disorder considered as a contraindication to intramuscular injection or blood draw.~9. Child's parent(s) or legal guardian(s) are not able to comprehend and to follow all required study procedures for the whole period of the study.~10. Receipt of any investigational or non-registered product since birth (3 month prior) or are expected to receive during the study period.~11. Family members or household members of site research staff.~12. Any clinically-significant chronic or progressive disease according to judgment of the investigator (pulmonary, cardiovascular, renal, hepatic or endocrine functional abnormality) or a congenital anomaly/known cytogenic disorder (e.g., Down's syndrome).~13. History or any illness/condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.

- Gender: ALL
- Minimum Age: 85 Days
- Maximum Age: 119 Days
- Healthy Volunteers: t

Study Arms:
- rMenB+ACWY (Type: EXPERIMENTAL): Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
- rMENB (Type: ACTIVE_COMPARATOR): Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
- MenACWY (Type: ACTIVE_COMPARATOR): Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete